FDASIA: The Perfect Name for PDUFA V
This article was originally published in RPM Report
Executive Summary
The House and Senate negotiators picked the perfect acronym for the newest version of the Prescription Drug User Fee Act: FDASIA – as in FDA/Asia with a dose of Fantasia. On the safety side, the law will help FDA adapt to a global supply chain and especially the rise of China and India. As for accelerating drug development, the fantasy may outpace the reality.
You may also be interested in...
“Breakthrough Therapy”: New Pathway in FDASIA May Point The Way To Future Reforms
A new FDA designation process for “breakthrough” drugs is one of the few “innovation” features of the FDA Safety & Innovation Act. It is likely to be very attractive to biotech sponsors, though its impact on actual product approvals is uncertain at best. The real “breakthrough,” though, may be in the collaborative model that led to the legislation – and that is an important message for sponsors hoping for bigger reforms ahead.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.